glycoinositolphospholipid GY

Glycoinositolphospholipid GY (GIPL-GY) is a specific glycolipid antigen extracted from the cell membrane of the protozoan parasite *Leishmania guyanensis*. GIPLs are major surface glycoconjugates in *Leishmania* species, characterized by a conserved glycan core (Manα1-4GlcNα1-6) linked to a phosphatidylinositol anchor. In the context of biotechnology and immunology, GIPL-GY is primarily investigated as a diagnostic antigen for American Tegumentary Leishmaniasis (ATL) and as a potential vaccine candidate. It functions as a potent immunomodulator by acting as an agonist for Toll-like receptor 4 (TLR4), which triggers the innate immune system to produce pro-inflammatory cytokines such as TNF-α and IL-12. Research conducted by institutions such as the Federal University of Minas Gerais has demonstrated that GIPL-GY can elicit specific antibody responses in infected patients, making it a valuable tool for serological diagnosis and a target for developing protective Th1-type immunity against leishmaniasis.

Other names

Glycoinositolphospholipid from Leishmania guyanensisL. guyanensis GIPLLeishmania guyanensis glycoinositolphospholipid